Trials / Not Yet Recruiting
Not Yet RecruitingNCT06681337
Universal CAR-T Cell Therapy for Refractory Lupus Nephritis
A Clinical Study of the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 for the Treatment of Refractory Lupus Nephritis
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
Detailed description
This study is a non-randomized, open-label, single-arm clinical trial designed to assess the efficacy and safety of combination therapy for refractory lupus nephritis using universal CAR-T cells targeting BCMA and CD19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCMA CART + CD19 CART | BCMA CART + CD19 CART |
Timeline
- Start date
- 2024-11-25
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-11-08
- Last updated
- 2024-11-08
Source: ClinicalTrials.gov record NCT06681337. Inclusion in this directory is not an endorsement.